BLU News and Press, BELLUS Health Inc. From 11/15/22

BELLUS Health press release ( NASDAQ: BLU ): Q3 GAAP EPS of -$0.20 misses by $0.03 . Revenue of $4K (fat Y/Y). Ended third quarter 2022 with $364.4M in cash, cash equivalents and short-term investments; Cash runway extended to the second half of 2025 and through ex...

- Initiated CALM Phase 3 program with topline data expected for CALM-1 and CALM-2 in the second half of 2024 and 2025, respectively - - Ended third quarter 2022 with US$364.4 million in cash, cash equivalents and short-term investments; Cash runway extended to the seco...

BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and other cough hypersensitivity indicati...

The S&P/TSX Composite Index climbed 360 points on Friday, September 9. Every sector finished the day in the black, with battery metals, health care, and information technology sectors emerging as the standouts. That said, investors have been forced to wrestle with volatility in ...

Summary BELLUS Health intends to initiate two phase 3 studies in Q4 of 2022; these will be CALM-1 and CALM-2 studies using BLU-5937 for treatment of patients with refractory chronic cough. Final results from the phase 3 CALM-1 and CALM-2 studies using BLU-5937 for treatment of pat...

BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and other cough hypersensitivity indicati...

BELLUS Health press release ( NASDAQ: BLU ): Q2 GAAP EPS of -$0.18 misses by $0.01 . Revenue of $0.04M (flat Y/Y) beats by $0.04M . For further details see: BELLUS Health GAAP EPS of -$0.18 misses by $0.01, revenue of $0.04M beats by $0.04M

- Completed positive End-of-Phase 2 meeting with the Food and Drug Administration (“FDA”) and received scientific advice from the European Medicines Agency (“EMA”) to support design of its CALM Phase 3 program, which is expected to initiate in Q4 2022 -...

BELLUS Health Inc. (NASDAQ: BLU)(TSX: BLU) (the “Company” or “BELLUS Health”) announced today that it has completed its previously-announced underwritten public offering in Canada and the United States (the “Offering”) of 16,540,541 common share...

After the company announced the launch and pricing of its latest public stock offering, shares of BELLUS Health (NASDAQ: BLU) are down by around 12.1% as of 10:53 a.m. Thursday. The offering is for 16,540,541 shares, priced at $9.25 per share, which is currently a slight premium ove...